The latest research on metastatic tumor anti-CTLA-4 therapy shows a high risk of developing irAEs; the most remarkable irAEs include cutaneous diseases, like rash and pruritus, along with gastrointestinal tract irAEs, such as colitis. The gene discussed is CTLA4; the disease is metastatic neoplasm.